VTGN Earnings & Financial Statements
VistaGen Therapeutics, Inc.
$0.21
-$0.01(-3.82%)
38
Overall
60
Value
18
Tech
36
Quality
Market Cap
$9.17M
Volume
945.49K
52W Range
$0.20 - $1.03
Target Price
$0.97
VTGN earnings and financial statements: VistaGen Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VTGN Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $486.0K | $1.06M | -$227.0K | $1.11M |
| Operating income | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M |
| EBITDA | -$71.39M | -$55.33M | -$32.14M | -$58.74M | -$47.05M |
| Net income | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M |
| EPS (diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | $-7.50 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $48.56M | $84.34M | $123.65M | $21.09M | $74.64M |
| Total liabilities | $13.04M | $13.95M | $9.37M | $9.01M | $9.93M |
| Shareholders’ equity | $35.52M | $70.39M | $114.29M | $12.08M | $64.72M |
| Cash and equivalents | $30.79M | $67.13M | $119.17M | $16.64M | $68.14M |
| Long-term debt | $249.0K | $948.0K | $1.57M | $2.12M | $2.61M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$66.44M | -$42.10M | -$25.81M | -$49.72M | -$45.26M |
| Capital expenditure | - | -$191.0K | -$61.0K | -$212.0K | -$200.4K |
| Free cash flow | -$66.44M | -$42.10M | -$25.87M | -$49.93M | -$45.26M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VTGN | $0.21 | -3.8% | 945.49K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get VistaGen Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW